ALNY vs REPX · P/E 76, rev $1.29B vs P/E 12, rev $279.7M
Alnylam Pharmaceuticals Inc (ALNY) versus Riley Exploration Permian Inc (REPX) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Riley Exploration Permian Inc (REPX) is a oil & gas e&p company listed on AMEX.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported REPX revenue for 2026-06-30 was $279.7M. Net income was $16.9M. REPX currently screens at market cap $727.0M and trailing P/E 11.7.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. REPX currently screens at market cap $727.0M and trailing P/E 11.7.
Not investment advice. Open the ALNY and REPX stock pages for the full models.
Not investment advice.